[Sponsored] A new eBook explores how using real world data from patients can help drug developers improve outcomes for non-small cell lung cancer and other patient populations.

The post How to Use Real-World Data to Improve Drug Development, Starting with the Patient Journey appeared first on MedCity News.

[Sponsored] A new eBook, sponsored by PurpleLab, examines how a significant number of patients with non-small cell lung cancer miss out on optimal care due to gaps in biomarker testing, socioeconomic barriers, incomplete patient journey data, and what can be done to change that.

The post How Real-World Data Is Reshaping the NSCLC Patient Journey appeared first on MedCity News.

When applied with a rigorous, subject-matter-expert guided process, AI-currated RWD is an essential resource giving life science organizations new power to monitor the diverse variety of ways drugs are actually utilized post-approval. 

The post Blinded by Science: The Importance of RWD and Post-market Surveillance appeared first on MedCity News.

This year will be the turning point from AI “hype” to the adoption of meaningful AI and digital health solutions in pharma. Here four predictions.

The post Digital Innovation in Pharma: What Will 2026 Bring? appeared first on MedCity News.

[Sponsored] Using RWD to understand SDOH factors faced by patients with non-small cell lung cancer paves the way for improving health equity and more effective treatments for more people.

The post The Role of RWD in Revolutionizing Clinical Trial Design appeared first on MedCity News.

[Sponsored] For non small cell lung cancer patients, a zip code can mean the difference between diagnosis time and treatment options.

The post SDOH in Oncology: Mapping Out How Zip Code Can Affect Care Is a Critical Step to Improving Outcomes appeared first on MedCity News.

[Sponsored] This article is part of a series on eliminating blind spots in the patient journey by leveraging real-world data.

The post Using RWD, SDoH and Patient Mapping to Eliminate Blind Spots from the Patient Journey appeared first on MedCity News.

The application of AI technology is part of a carefully orchestrated effort dependent on human intelligence, and the collaboration of physicians, disease-specific specialists, nurses, data scientists, and technologists. Done right, these efforts can lead to profound benefits, and offer a promising future for clinical research and patient care.

The post Augmenting Brain Power: Real-World Data, Advanced Analytics, and the Future of Clinical Trials appeared first on MedCity News.

Technology that offers tools that conform, de-identify, link and aggregate data and data science tools like AI, machine learning and advanced analytics, can help those researching rare diseases overcome the hurdles they face in discovery and development. 

The post Data Technology + RWD Are Positive for Rare Disease Treatment appeared first on MedCity News.

The ability to harness real-world insights at scale empowers life sciences companies and clinicians to develop more targeted therapies, improve patient outcomes, and drive evidence-based innovation in BPH treatment.

The post Harnessing Real-World Data and AI to Advance Research and Treatment for Benign Prostatic Hyperplasia appeared first on MedCity News.

[Sponsored] A one-size fits most approach to clinical trial recruitment is no longer effective. A webinar discussion emphasized the need for patient-level data to shape each phase of a drug’s lifecycle, from clinical development to market access.

The post How Can RWD Transform the Patient Journey? appeared first on MedCity News.

[Sponsored] The webinar, sponsored by PurpleLab and scheduled for May 22, will explore how healthcare sector companies can leverage real world data (RWD) with a focus on lung cancer.

The post Using RWD to Improve Clinical Trial Recruitment, Endpoints, and Inform Market Access Strategies appeared first on MedCity News.

[Sponsored] PurpleLab and Genentech executives will explore how to leverage real world data to eliminate blind spots in the patient journey — informing every phase of a drug’s lifecycle, from clinical development to market access — in a May 22 webinar.

The post Improving the Patient Journey in Drug Development appeared first on MedCity News.

Engaging in data sharing, observational cohort research, and deeper analysis of available data to yield further insights can drive improved results for patients, making label and cohort extension faster and more robust.

The post How Real-World Data Can Support Label Extension And Safer Use Of Novel Therapies appeared first on MedCity News.

Considering the lack of high quality data, companies that excel in compiling and managing data effectively are attracting interest from industry partners and distinguishing themselves from their rivals. Here are some of the ways emerging AI applications are fueling and redefining the need for RWD across HCLS.

The post How AI is Accelerating the Need for Real World Data in Healthcare and Life Sciences appeared first on MedCity News.

[Sponsored] A new report by datma explores how companies can use federated data models to scale RWD.

The post Federated Models Offer New Paradigm for Data Monetization in Healthcare appeared first on MedCity News.

Try a variety of LLM-based tools yourself. Understand the risks, limitations, and who is working on putting quality frameworks and guardrails in place. Engage your employees and partners in discussions about what might now be possible.

The post A CEO’s Guide to AI Exploration: Transforming Organizations and Mindsets appeared first on MedCity News.

Enabling RWD-driven drug development accelerates the approval of more effective and affordable treatments. This approach successfully identifies patient patterns and density indicators and maps causal pathways.

The post Ignoring RWD Endangers Drug Development appeared first on MedCity News.

By allowing study teams to design and conduct more inclusive and/or relevant studies, real-world data can enhance the standard of care and ultimately improve patient outcomes.

The post Leading Clinical Trial Recruitment Strategies Center Around Real-World Data appeared first on MedCity News.

Liberating the genetics, laboratory and pharmacy data that sits deep within healthcare subsystems, while protecting patient information and navigating the global regulatory landscape, is no easy task but would greatly help in the treatment of diseases.

The post Liberating real-world data for use in clinical trials appeared first on MedCity News.

The researchers wrote that RWE could complement trials, but that observational methods are unlikely to take away the need for traditional clinical studies.

The post Study finds real-world evidence replicates less than one-fifth of clinical trials appeared first on MedCity News.

Parexel, one of the largest CROs in the world, said the partnership would involve connecting real-world data across the clinical trials it conducts.

The post Parexel, Datavant partner on using real-world data in clinical trials appeared first on MedCity News.

Aetion President Jeremy Rassen said in an interview on the sidelines of the CB Insights Future of Health conference that rare diseases and Phase IV safety studies would be examples of situations better suited to real-world evidence.

The post Aetion exec sees real-world evidence, randomized trials playing complementary roles appeared first on MedCity News.